Aterovax SA

Current treatments for atherosclerosis use markers and therapeutic targets that are consequences of the disease. Aterovax SA is attempting a more direct route. By basing its research and pipeline on sPLA2, a family of secreted phospholipases that are mediators in the inflammatory process involved in atherosclerosis, it hopes to create products that are either predictive of cardiovascular disease rather than simply diagnostic, or that can stop the development of unstable atherosclerotic plaques.

24 Rue du Faubourg St. Jacques

Faculty of Medicine René Descartes

More from Archive

More from Scrip

EU 15% Tariff Deal Still Leaves Questions For Pharma

 

A single 15% tariff rate on imports from Europe includes pharmaceuticals, but it remains unclear if the trade deal will exclude generics or if Trump will offer a grace period.

Roche Unveils Alzheimer’s Phase III Plan And Preclinical Study

 

The trontinemab Phase III study is due to get underway this year, with Roche confident its brainshuttle technology will help it surpass approved rivals.

Bayer’s Elinzanetant Is Latest Drug Hit By FDA Review Delays

 
• By 

Comes Days After PDUFA Pushback For GSK's Blenrep.